236406-40-9

Basic information

• Product Name: 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate;8-Boc-2-benzyl-2,8-diaza-spiro[4.5]decane;2,8-Diazaspiro[4.5]decane-8-carboxylic acid, 2-(phenylMethyl)-, 1,1-diMethylethyl ester;2-(Phenylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
• CAS NO: 236406-40-9
• Molecular Formula: C20H30N2O2
• Molecular Weight: 330.47
• Mol File: 236406-40-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 428.9°C at 760 mmHg
• Flash Point: 213.2°C
• Appearance: /
• Density: 1.10
• Vapor Pressure: 1.47E-07mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(236406-40-9)
• EPA Substance Registry System: 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(236406-40-9)

Safety Data

• Hazardous Substances Data: 236406-40-9(Hazardous Substances Data)

Usage

General Description

2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER is a chemical compound that belongs to the spiro compounds class. It is derived from the carboxylic acid tert-butyl ester and contains a benzyl group attached to the spirodecane ring system. 2-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER has potential applications in the pharmaceutical and agrochemical industries due to its unique structure and properties. It may be used as a building block in the synthesis of new drugs or as a precursor for the development of new agrochemicals. Further research and exploration of its potential uses and properties are warranted to fully understand its applications in various industries.

InChI:InChI=1/C20H30N2O2/c1-19(2,3)24-18(23)22-13-10-20(11-14-22)9-12-21(16-20)15-17-7-5-4-6-8-17/h4-8H,9-16H2,1-3H3

Upstream product

• 236406-39-6 2,8-diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 144-55-8 sodium hydrogencarbonate 
• 929301-95-1 C₁₅H₂₉NO₈S₂ 
• 100-46-9 benzylamine 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 146603-99-8 1-(1,1-dimethylethyl) 4-ethyl 4-(2-propenyl)-1,4-piperidinedicarboxylate 
• 1228603-43-7 4-(2-oxoethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 1221818-05-8 tert-butyl 2-benzyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 100-52-7 benzaldehyde 
• 236406-38-5 1,1-dimethylethyl 4-(2-hydroxyethyl)-4-(hydroxymethyl)-1-piperidinecarboxylate 
• 203662-20-8 8-t-butoxycarbonyl-3-hydroxy-2-oxa-8-azaspiro[4.5]decane 
• 236406-37-4 tert-butyl 4-(hydroxymethyl)-4-(prop-2-en-1-yl)piperidine-1-carboxylate 

Downstream Products

• 236406-39-6 2,8-diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 867009-61-8 2-benzyl-2,8-diazaspiro[4.5]decane 

Relevant articles and documents

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

A series of new 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC 0.15 μM) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

N-acyl cyclic amine derivatives

The invention relates to compounds represented by the general formula [I][wherein Ar means an aryl group or a heteroaryl group which may have a substitutive group selected from a group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; R1 means a C3-C6 cycloalkyl group which is substitutable with a fluorine atom; R2 and R4 mean hydrogen atoms, groups represented by -(A1)m-NH-B or the like; R3 and R5 mean hydrogen atoms, C1-C6 aliphatic hydrocarbon groups or the like which are substitutable with a lower alkyl group(s); n means 0 or 1; and X means an oxygen atom or a sulfur atom]. Compounds according to the invention, since they not only have potent selective antagonistic activity against muscarinic M3 receptors but also exhibit excellent oral activity, durability of action and pharmacokinetics, are very useful as safe and effective remedies against respiratory, urinary and digestive diseases with little adverse side effects.